IMVT Immunovant, Inc.

Nasdaq Biological Products, (No Diagnostic Substances) DE CIK: 0001764013
AI RATING
SELL
68% Confidence

Investment Thesis

Immunovant exhibits strong revenue growth of 229% YoY but is deeply unprofitable with -$357.8M net income and severe cash burn of -$312.3M annually. While the company maintains a robust cash position of $994.5M with zero debt, current burn rates provide only 3-4 years of runway, creating existential pressure for profitability or dilutive financing.

Strengths

  • + Strong cash position of $994.5M with zero debt provides multi-year operational runway
  • + Exceptional revenue growth of 229% YoY suggests meaningful market traction or recent commercialization milestone
  • + Excellent liquidity ratios (15.74x current and quick) ensure operational flexibility

Risks

  • ! Severe operating losses of -$354.7M with unsustainable net margin of -1434% indicating pre-profitability stage
  • ! Annual cash burn of -$312.3M limits runway to approximately 3-4 years absent material revenue acceleration
  • ! Minimal revenue base of $24.9M makes growth rate potentially unsustainable; company remains pre-commercial or early-stage

Key Metrics to Watch

Financial Metrics

Revenue
24.9M
Net Income
-357.8M
EPS (Diluted)
$-2.04
Free Cash Flow
-312.3M
Total Assets
1.1B
Cash
994.5M

Profitability Ratios

Gross Margin N/A
Operating Margin -1,421.7%
Net Margin -1,434.0%
ROE -36.3%
ROA -34.0%
FCF Margin -1,251.6%

Balance Sheet & Liquidity

Current Ratio
15.74x
Quick Ratio
15.74x
Debt/Equity
0.00x
Debt/Assets
6.3%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-04-11T19:21:27.466973 | Data as of: 2025-12-31 | Powered by Claude AI